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A novel in vitro potency assay of 
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Tan5, Sukanya Eursakun1, Choo Hock Tan6, Bunkuea Chantrathonkul1, Wongsakorn 
Wongwadhunyoo7, Sirida Youngchim4 & Nget Hong Tan5
Snake envenomation is an important medical problem. One of the hurdles in antivenom development 
is the in vivo assay of antivenom potency which is expensive, gives variable results and kills many 
animals. We report a novel in vitro assay involving the specific binding of the postsynaptic neurotoxins 
(PSNTs) of elapid snakes with purified Torpedo californica nicotinic acetylcholine receptor (nAChR). The 
potency of an antivenom is determined by its antibody ability to bind and neutralize the PSNT, thus 
preventing it from binding to nAChR. The PSNT of Naja kaouthia (NK3) was immobilized on microtiter 
wells and nAChR was added to bind with it. The in vitro IC50 of N. kaouthia venom that inhibited 50% of 
nAChR binding to the immobilized NK3 was determined. Varying concentrations of antisera against N. 
kaouthia were separately pre-incubated with 5xIC50 of N. kaouthia venom. The remaining free NK3 were 
incubated with nAChR before adding to the NK3 coated plates. The in vitro and in vivo median effective 
ratio, ER50s of 12 batches of antisera showed correlation (R2) of 0.9809 (p < 0.0001). This in vitro assay 
should be applicable to antisera against other elapid venoms and should reduce the use of live animals 
and accelerate development of life-saving antivenoms.
Snake envenomation is an important medical problem especially in the developing world. It has been esti-
mated that around 421,000–2.5 million people are envenomed annually with about 20,000–94,000 fatalities1. 
Antivenoms (AVs) are the rationale and the most effective therapy of snake envenomation. However, this serious 
public health problem has so far been neglected and effective, affordable antivenoms remain unavailable in many 
parts of the developing world. Recently, efforts from a number of research institutions are underway to solve this 
problem2.
In the development and production of an AV, at least two major steps are involved: an effective immunization 
program and the pre-clinical testing to assess the neutralizing potential of the AV against the lethal effects of 
homologous and heterologous venoms. The accepted AV potency assay is the standard murine lethality assay to 
determine the median lethal dose (LD50) that estimates the lethality of the venom and the median effective dose 
(ED50) of the AV3, 4. For this in vivo assay, three to five mice per venom dose are used and the total of about 6 
different doses are tested. Thus, about 30 mice are needed for the determination of the LD50 of a venom. Similarly, 
about 30 mice are needed for the ED50 determination of an AV against a venom. Therefore, a large number of 
mice will be used for the in vivo neutralization assays. For example, the number of mice required by European 
Pharmacopoeia using this method to test the activity of one European viper venom antiserum (LD50 and ED50 
tests combined) against five venoms, is 374 mice per batch of antivenom5. Using this figure, testing a pan-specific 
AV against 27 different venoms6 would require about 2,020 mice. The assay is very costly, laborious and can give 
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highly variable results. Moreover, some lethality studies have been shown to be inconsistent, suggesting that 
rodent death may not measure relevant efficacy outcomes in humans7. Lastly, witnessing the suffering and death 
of a large number of animals is the most difficult part of the experiment for many. In Buddhist countries like 
Thailand, most, if not all, laboratory personnel and graduate students refuse to do such experiments. Thus, it is 
becoming increasingly difficult to perform the in vivo assay for ethical and religious, as well as regulatory reasons.
For the above reasons, various types of in vitro neutralization assays have been developed to be used in place 
of, or to reduce the number of the in vivo assay. It has been reported that venom toxicity and effectiveness of AV 
can be studied using the chick biventer cervicis preparation8–10. This assay was used for screening AVs against 
the neurotoxic effects of venoms11. However, this in vitro assay requires the preparation of chick biventer cervicis 
muscles and the assay is laborious and time-consuming. In vitro neutralization of some venom enzymatic activ-
ities have been studied for use in AV potency assay12. It was shown that the neutralization of phospholipase A2 
activities by antivenom against Micrurus nigrocinctus highly correlated with the in vivo neutralization activity. 
Also, the inhibition of indirect hemolytic activity induced by phospholipase A2 was also shown to correlate well 
with the in vivo potency of a polyspecific antivenom13. However, these assays are applicable only to antivenoms 
directed against venoms with enzymatic activities that parallel the lethality of the venoms.
Numerous investigators have studied and reported the use of ELISA for AV potency determinations together 
with the correlation between the results of the in vitro and in vivo neutralization assays14–20. However, the “neu-
tralizing potency” described as “in vitro ELISA titer” occasionally did not correlate well with the in vivo neutral-
izing activity. For example, Ibrahim and Farid21 studied the lethality-neutralizing potency, ELISA antibody level 
and the avidity indexes of a polyvalent antivenom against seven snake venoms. They showed poor correlation 
between the in vivo and in vitro assays with the in vitro assays always giving high values. ELISA has at times been 
criticized on the grounds that the antigen-antibody ‘binding’ reaction measured cannot be assumed to be the 
same as the ‘neutralization’ reaction of the antigen.
Elapid snakes (cobras, kraits and mambas) produce the lethal postsynaptic neurotoxins (PSNTs) which bind 
specifically and quasi-irreversibly with nicotinic acetylcholine receptor (nAChR) at the muscle end-plate22, 23. This 
binding results in the inhibition of neuromuscular transmission which can lead to respiratory arrest and death23. 
Thus, it should be possible to develop an in vitro functional assay to test antivenom against elapid venoms based 
on the ability of the antivenom antibodies to inhibit the binding of PSNTs to nAChR. Such an in vitro assay would 
closely mimic the lethality reactions of PSNTs of the elapids in vivo, in particular cobras (Naja sp.). Cobras are in 
general listed as Category 1 of medically important snakes throughout most parts of Asia and Africa4, 24.
An in vitro potency assay based on PSNT binding to nAChR was previously studied for the venom of coral 
snake Micrurus nigrocinctus12. It was found that, the ED50 of the horse antisera against M. nigrocinctus in neu-
tralizing the lethal effect of the venom did not correlate with the antivenom ability to inhibit the nAChR-binding 
activity but correlated well with the inhibition of the venom phospholipase A2 activity.
By using a different reaction scheme and conditions from that studied above12, we report here the develop-
ment of a novel in vitro potency assay of monospecific antisera against the venom of the Thai monocled cobra 
Naja kaouthia based on nAChR binding. The assays gave excellent correlation (R2 = 0.9809; p < 0.0001) with the 
corresponding in vivo assay using mice. This in vitro assay should be useful in reducing or partially replacing the 
in vivo assays used to test antivenoms against N. kaouthia and other elapid venoms.
Results
Development of the in vitro neutralization assay using nAChR-PSNT binding. The optimal con-
centrations of NK3, nAChR, rat anti-nAChR antibody and goat-anti-rat HRP conjugate in the in vitro potency 
assay. The optimal concentrations of NK3, nAChR, rat anti-nAChR antibody and goat-anti-rat HRP conjugate 
used in the in vitro potency assay were studied as described in Materials and Methods (step: pre-incubation 2). 
The results are shown in Fig. 1. As the concentration of NK3 used to coat the microtiter plate increased, the signal 
as measured by the OD450nm increased. This was also observed when the concentration of nAchR used to bind the 
immobilized NK3 was increased. To economize on the nAChR available while obtaining reasonably high OD450nm 
signal, it was decided to use 15 µg/ml of NK3 for coating the plates and 0.707 µg/ml of nAChR for binding to the 
NK3 coated plate. A 1:1600 dilution of rat anti-nAchR serum and a 1:4500 dilution of goat anti-rat-IgG conju-
gated HRP were used.
Inhibition of nAChR binding to NK3-coated plate by N. kaouthia venom or N. kaouthia cytotoxin. Crude 
N. kaouthia venom was used to determine the 50% inhibition of nAChR binding (in vitro IC50). In the first step, 
crude N. kaouthia venom at various concentrations was incubated with the purified nAChR (0.707 µg/ml) for 1 
hr at 25 °C. The solution was then transferred to NK3 coated plates. The concentration of the crude venom that 
reduced nAchR binding by 50% was defined as the IC50. The results (Fig. 2) showed that the IC50 of N. kaouthia 
was 0.0281 µg/ml.
To study the specificity of the nAChR binding, N. kaouthia cytotoxin I at various concentrations (0.4875 to 
0.0152 µg/ml) was tested as described above. It was shown (Fig. 2) that the cytotoxin had no effect on the nAChR 
binding. Thus, the inhibition reaction was specific to the postsynaptic neurotoxins.
Neutralization of N. kaouthia venom by horse monospecific antisera as determined by nAChR binding to the 
NK3-coated plate. Twelve horse monovalent anti-N. kaouthia sera were serially diluted 2-fold from 1:500 to 
1:512,000 and the dilutions were separately incubated with 5xIC50 of N kaouthia venom (1.4029 µg/ml) in the 
‘Pre-incubation 1’ experiment. After ultrafiltration and ‘Pre-incubation 2’, the reaction mixtures were added to 
the NK3-coated plates. The binding of the free nAChR to the plate was measured at OD450nm and the results are 
shown in Fig. 3.
www.nature.com/scientificreports/
3SCIenTIFIC REpoRTS | 7: 8545  | DOI:10.1038/s41598-017-08962-3
The in vitro median effective ratio (ER50s), expressed as µg of venom neutralized per µl of antiserum, and the 
in vivo ER50s (mg of  venom neutralized per ml of antiserum) of the 12 horse antisera are shown in Table 1. The 
correlation coefficient, R, between the in vitro ER50s and the in vivo ER50s was 0.9904, and the coefficient of deter-
mination for the regression model was R2 = 0.9809 (p < 0.0001), as shown in Fig. 4.
Discussion
It is reported here the first successful development of an in vitro potency assay for antiserum against an elapid 
snake based on nicotinic acetylcholine receptor binding. The reactions employed in the in vitro assay closely 
mimicked those of the in vivo toxicological reactions of the elapid postsynaptic neurotoxins. Unlike the ELISA 
which at times gave poor correlation with in vivo assay and has often been criticized in that the antibody binding 
did not necessarily result in toxin neutralization, the present in vitro assay involved the binding and neutralization 
by the antisera antibodies of the lethal snake toxins thus preventing them from binding to nAchR. The correlation 
Figure 1. Determinations of optimal concentrations of NK3, purified nAChR, rat anti-nAChR serum and goat 
anti-rat IgG conjugated HRP. A: goat anti-rat IgG-HRP conjugate at 1:4500, B: goat anti-rat IgG-HRP conjugate 
at 1:6000.
Figure 2. The inhibition of nAChR binding to the NK3 coated-plate by N. kaouthia venom and by N. kaouthia 
cytotoxin I. nAChR binding were expressed as mean ± S.D. of 4 determinations.
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Figure 3. Effects of horse anti-N. kaouthia sera in neutralizing N. kaouthia venom as determined by nAChR 
binding to NK3-coated plate. nAChR binding were expressed as mean ± S.D. of 4 determinations.
Horse
In vitro ER50 ± S.D. (µg 
venom/µl antiserum)
In vivo ER50 (mg 
venom/ml antiserum)
Nk-A 0.8598 ± 0.1089 0.36 (0.24–0.54)
Nk-B 3.8693 ± 0.2887 1.57 (1.05–2.36)
Nk-C 1.2039 ± 0.2074 0.69 (0.46–1.03)
Nk-D 1.0055 ± 0.1368 0.51 (0.34–0.76)
Nk-E 0.7526 ± 0.2438 0.32 (0.21–0.48)
Nk-F 0.5911 ± 0.0433 0.31 (0.21–0.47)
Nk-G 0.6456 ± 0.0727 0.36 (0.24–0.53)
Nk-H 0.2921 ± 0.0564 0.18 (0.12–0.27)
Nk-I 0.4060 ± 0.1322 0.17 (0.11–0.26)
Nk-J 0.1307 ± 0.0467 0.14 (0.09–0.20)
Nk-K 0.1748 ± 0.0031 0.15 (0.10–0.23)
Nk-L 0.1712 ± 0.0530 0.17 (0.12–0.26)
Table 1. In vitro and in vivo ER50s of horse anti-N. kaouthia sera in neutralizing N. kaouthia venom. For 
each batch of antiserum, the in vitro ER50 was mean ± S.D. from 4 determinations while the in vivo ER50 was 
median ± 95% C.I. (C.I. = confidence level).
Figure 4. Regression between the nicotinic binding efficacy (Log2 [in vitro ER50]) and the lethality 
neutralization efficacy (in vivo ER50). R2: Coefficient of determination. In vitro ER50 values were expressed 
as mean ± S.D. (μg venom/μl antiserum) of 4 determinations. In vivo ER50 values were expressed as median 
dose ± 95% C.I. from serial dose-response study in mice (n = 4–5 mice per dose). Footnote: For each batch of 
antiserum, the in vitro ER50 was mean ± S.D. from 4 determinations while the in vivo ER50 was median ± 95% 
C.I. (C.I. = confidence level).
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between the in vivo assay using mice and the developed in vitro assay was very high as supported by the correla-
tion coefficient of R = 0.9904.
An in vitro assay based on PSNT binding to nAchR was studied by Stiles25, 26 and Alape-Giron et al.12, 27. Using 
an ELISA format, the bindings of purified nAchR from T. californica to the immobilized long and short PSNTs 
were shown to be specific. Furthermore, these researchers showed that horse antivenom against M. nigrocinc-
tus nigrocinctus venom contained antibodies that inhibited the binding of the venom α-neurotoxins to purified 
nAchR, and reversed the binding of the toxins already complexed with the receptor12. The antivenom ED50 in 
neutralizing the lethal effect of the venom was shown not to correlate with the antivenom’s ability to inhibit the 
nAchR-binding activity (r = 0.34; p > 0.05) but correlated well with the inhibition of phospholipase A2 activity. 
From these results, they concluded that the lethality of the venom was the result of the combined actions of 
various toxins12 and recent proteomics results have shown that the short-chain α-neurotoxins are likely to play a 
leading role in the lethality induced by this venom28.
The in vitro assay reported here involved reaction schemes that were different from those reported by 
Alape-Giron et al.12. Two salient features of the present assay protocol were as follows.
First, the two crucial reactions i.e., the antibody-venom toxins reaction, and the toxin-nAChR reaction, were 
carried out in solution rather than on solid surface. This was to allow for total exposure of the reactants’ surface 
residues resulting in more complete binding with their counterparts, and also to avoid any possible steric interac-
tions between the two high molecular weight reactants (IgG and nAchR) which are likely to be more pronounced 
on solid surface.
Second, after the venom-antibody reaction in ‘Pre-incubation 1’, the antibodies, free or toxin bound, were 
removed from the reaction mixture by ultrafiltration. This was important in that if these antibodies were not 
removed, any free excess antibody remaining in the ‘Pre-incubation 1’ reaction could react with the immobilized 
toxins in the final reaction resulting in reduced binding of nAChR (added in the later step) to the immobilized 
toxins. Furthermore, since the dissociation constant of toxin-antibody complexes are usually in the micromolar 
range while the toxin-nAchR dissociation constant is closer to nanomolar range29, it is conceivable that, without 
the ultrafiltration to remove the antibodies, the antibody-bound toxin might dissociate and form tighter com-
plex with nAChR. These reactions would shift the equilibrium of the toxin-antibody reaction, and the measured 
amount of nAChR bound to the immobilized toxin would also be reduced.
The described assay procedure was thought to improve the reactions involved and to eliminate or minimize 
any inaccuracy of reactant concentrations measured; leading to highly correlated in vitro and in vivo results.
It should be noted in Fig. 3 that at higher concentrations of the antisera Nk-A Nk-B and Nk-I, the nAChR 
bindings were decreased. This phenomenon, often observed in immunoassays, is known as the ‘prozone phenom-
enon’ or ‘hook effect’ where, at excess concentration of antibody, immunochemical reactions e.g., hemagglutina-
tion, were inhibited or become less pronounce30, 31.
The in vitro potency assay described here should be applicable to antivenoms against most, if not all, elapids 
whose venoms contain mainly or exclusively postsynaptic neurotoxins as major lethal components. However, the 
usefulness of the assay for some elapids producing other lethal toxins e.g., some Bungarus venoms may contain, in 
addition to PSNTs, presynaptic neurotoxins (β-neurotoxins) which are highly lethal32, 33. Thus, this in vitro nAchR 
binding assay which worked well with antisera against the Naja venoms might not work as well with some of the 
Bungarus venoms, depending on the abundance of the β-neurotoxins present in the particular venom and their 
role to the overall neurotoxicity.
Since effective, affordable antivenoms against snake venoms remain unavailable in many parts of the world2, 
studies were being made to produce pan-specific antivenoms that cover multiple snake venoms from wide geo-
graphical areas6. Such a pan-specific antivenom could be produced in large volume and, due to the economy of 
scale, could be produced at low cost. However, in the development of such pan-specific antivenoms, a large num-
ber of mice would be needed to assay its efficacy against many homologous and heterologous venoms, and over 
the years, the cumulative number of mice used will be even more perturbing considering the need to repeat the 
assay from batch to batch of antivenom. With the developed in vitro assay described here, the development and 
production of poly-specific or pan-specific AVs should become easier and simpler. This should eventually result 
in saving the lives of mice and the victims of snake envenomation.
In conclusion, the assay should reduce the use of mice for potency assays for example, during the immuni-
zation program and/or fractionation process of antivenom production. In some cases, it may even replace the in 
vivo assay. The in vitro assay is less expensive, less biologically variable and could avoid the ethical and religious 
issues involved. The in vitro assay could facilitate the development and production of new and effective antiven-
oms, especially the pan-specific antivenoms which usually employ a large number of mice. The availability of 
new antivenoms combined with the reduction in production cost could, in turn, save the lives of more snakebite 
victims, which are mostly from the poorer regions of the world34.
Materials and Methods
Materials. Electroplaque tissue from Torpedo californica (Pacific electric ray) was obtained from Dr. Charles 
Winkler, Aquatic Research Consultants (San Pedro, CA, USA). Naja kaouthia (NK, formally known as Naja naja 
siamensis) venom from pool of several adult snakes of Thai origin and horse monovalent antisera against N. kao-
uthia was purchased from Queen Soavabha Memorial Institute (QSMI). Benzoquinonium dibromide was pur-
chased from Santa Cruz (Dallas, TX, USA). Goat against rat IgG conjugated with horse radish peroxidase (HRP) 
was purchased from Abcam (SF, USA). N. kaouthia postsynaptic toxin 3 (NK3, formally known as N. n. siamensis 
toxin 3) was purified as described by Karlsson et al.35. N. kaouthia cytotoxin (CTX-I) was purified as described by 
Tan et al.36. N-hydroxysuccinamide-Sepharose (NHS-Sepharose) was from GE Health Care. All other reagents 
were from Sigma Chemical, St Louis. Missouri, unless stated otherwise.
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Methods. Purification of nAChR and production of anti-nAChR antibody in rats. Purification of nAChR 
from T. californica electroplaque was carried out as described by Lindstorm et al.37. The purified receptor (10 µg) 
in 0.1 ml phosphate buffer saline (PBS) pH 7.4 was emulsified with Complete Freund adjuvant and injected sub-
cutaneously into each of the eleven Wistar rats. The second and third immunizations were carried out using the 
receptor emulsified in Incomplete Freund adjuvant and alum as the adjuvant, respectively. Blood of each rat was 
collected from the heart at the end of the experiment.
In vivo neutralizing activity of horse monospecific antisera against N. kaouthia venom. The intravenous median 
lethal dose, LD50, of N. kaouthia venom, 0.18 (0.12–0.27) µg/g, was adapted from Tan et al.38 of the same lab-
oratory using the same batch of venom as with the current work. Neutralization of lethality was conducted as 
described by Ramos-Cerrillo et al.39. Briefly, a challenge dose of the venom constituting 5 LD50 in 50 μl saline was 
pre-incubated at 37 °C for 30 min with varying dilutions of the pooled horse sera in normal saline, to give a total 
volume of 250 μl. The venom-antiserum mixture was subsequently injected into the caudal vein of the mice. The 
mice were allowed free access to food and water ad libitum and the number of survival after 48 h was recorded. 
The effective dose-50 (ED50) was determined as the volume of antiserum that protected 50% of the challenged 
mice from death using probit analysis. The neutralizing efficacy of the antiserum was also expressed as median 
effective ratio (ER50 ± 95% C.I. where C.I. is confidence interval) in mg venom/ml antiserum that gave 50% sur-
vival of the mice tested.
Development of the in vitro neutralization assay using nAChR-PSNT binding. Optimal con-
ditions of nAChR, rat anti-nAChR antibody and goat-anti-rat HRP conjugate binding to NK3 coated microtiter 
plate. This assay was the basic assay format for in vitro binding of solubilized, purified nAChR to the elapid 
PSNTs immobilized on the microtiter plate. Briefly, purified NK3 at various concentrations were coated to the 
microtiter wells (Polystylene High Binding 3590, Costar). After washing with 0.05% TWEEN 20 in phosphate 
buffered saline (PBST), the plate was blocked with 200 µl/well of PBST and 1% BSA for 2 hr. The purified nAChR 
(in PBS containing 0.05% Tween 20 and 0.15 BSA) at various concentrations were added to bind the immobilized 
NK3 by incubation at 25 °C for 1 hour. After 3 time washings to remove the unbound nAChR, rat anti-nAChR 
serum at various concentrations was added and incubated at 25 °C for 1 hr; this was followed by addition of 
goat-anti-rat-HRP conjugate (ab7097, Abcam) and incubated for 1 hr at room temperature. After 4 washes with 
PBST, 100 µl/well of freshly prepared substrate solution (0.01% w/w 3,3′,5,5′-tetramethyl benzidine and 0.003% 
hydrogen peroxide in 0.075 M citrate buffer, pH 5.0) was added. The plate was allowed to stand in the dark for 
30 min at 25 °C and the reaction was stopped by adding 25 µl of 4 N sulfuric acid. The absorbance of 450 nm was 
read against blank using an ELISA reader (Multiskan Go, Thermo Scientific). Optimal concentrations of NK3 
(used for coating the plate), nAChR, rat anti-nAChR antibody and goat-anti-rat-HRP conjugate were estimated 
and used in the experiments that followed.
Inhibition of nAChR binding to the NK3 coated plate by N. kaouthia venom. The ability of an elapid venom (N. 
kaouthia) which contains PSNTs to inhibit the binding of nAChR to NK3 immobilized plate was studied and was 
expressed as IC50 (venom concentration inhibiting 50% of the nAChR binding). In this assay, N. kaouthia crude 
venom at various concentrations was pre-incubated (25°C for 1 hr) with a fixed and optimal concentration of 
nAChR before the mixture was added to the NK3-coated plate and incubated at 25°C for 1 hour. This was fol-
lowed by additions of rat anti-nAChR serum at 1:1600 dilution and incubated at 25°C for 1 hr, followed by 1:4500 
diluted goat-anti-rat-HRP conjugate (Abcam) and incubated for 60 min at 25 °C. A parallel experiment using 
purified NK3 as the reference standard in place of the venom was also carried out. The concentration of the tested 
venom used in the pre-incubation step that inhibited 50% of the nAChR binding to the immobilized NK3 was the 
median inhibitory concentration (IC50) of that venom.
Inhibition of the N. kaouthia venom PSNTs from binding to nAChR by horse antisera. Using a format similar to 
that described above, an in vitro assay of horse antiserum potency (in vitro ED50) was carried out. Horse sera at 
various amounts (0.94 nl–0.96 µl) were pre-incubated at 37 °C for 1.5 hr with a fixed amount (5 × IC50) of N. kao-
uthia venom in 137 mM NaCl, 2.68 mM KCl, 8.10 mM Na2HPO4, 1.47 mM KH2PO4, 0.05% TWEEN20, 0.1% w/v 
BSA in a total volume of 480 µl. This was referred to as ‘Pre-incubation 1’. The mixture was then filtered through 
a 100 kDa MWCO ultrafiltration membrane (Amicon®) to remove antibody-toxin complexes, free antibodies 
and some other high molecular weight horse serum proteins. The filtrates (126 µl) containing the remaining free 
venom PSNTs were then incubated with an optimal amount of nAChR (14 µl in the same buffer) at 25o C for 1 
hr as described above and this was referred to as ‘Pre-incubation 2’. The mixtures containing any remaining free 
nAchR were then added to the microtiter wells immobilized with NK3, followed by the rat anti-nAChR antibody, 
goat-anti-rat HRP conjugate, etc. The reaction products were then processed as described above. Wells incubated 
with a non-immune horse serum in place of antisera were included as background control.
The percentage of nAChR binding was then determined using the following formula:
%nAChR binding (OD sample OD Ag control) 100
(OD max OD Ag control)
=
− ×
−
‘OD max’ represented the binding of nAChR (optimal amount) which was not pre-incubated with the venom 
or antiserum.
‘OD Ag control’ represented the binding of nAChR after being pre-incubated with 5 folds of IC50 of N kaouthia 
venom (and without antiserum in ‘Pre-incubation 1’).
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‘OD sample’ represented the binding of nAChR after nAChR (optimal amount) was pre-incubated with filtrate 
from ‘Pre-incubation 1’ (where 5 folds of IC50 of N. kaouthia venom was pre-incubated with various amount of 
antiserum).
From the results, dose–response curves of horse sera volumes vs percents of nAChR binding were constructed. 
The in vitro neutralizing activities (ED50s) represented the horse antiserum volumes at which the nAChR binding 
was inhibited by 50 percent compared to wells incubated with buffer in place of antisera. The in vitro median 
effective ratio, ER50, represented µg venom/µl antiserum that the nAChR binding was inhibited by 50% was cal-
culated. The results of the in vitro study on nAChR binding for every batch of the horse antisera (Nk-A to Nk-L) 
were presented as means ± S.D. of 4 determinations.
Ethics approval. Experiment involving rats was reviewed and approved by the Animal Care and Use 
Committee of the Faculty of Veterinary Science, Mahidol University, Protocol no. MUVS-2014–29 in accordance 
with the Guidelines of the National Research Council of Thailand. The protocol of animal study on mice was 
based on the guidelines given by the Council for International Organizations of Medical Sciences (CIOMS) and 
approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Malaya (Ethical 
clearance No. 2014-09-11/PHAR/R/TCH).
Miscellaneous procedures. Protein concentration was determined by the procedure described by Lowry 
et al.40 and by BCA Protein assay Kit (PierceTM) using bovine serum albumin as the standard. IC50 and ED50 values 
were determined using GraphPad Prism 5.0 program and BioStat 2009 version 5.8.3.0, respectively. The corre-
lation analysis was evaluated by linear regression using GraphPad Prism 5.0 software. In brief, the correlation 
coefficient R was determined from the linear regression model, and R2 (coefficient of determination) is the square 
of the correlation coefficient. An R2 of 0.8–1.0 indicates that the regression line well fits the data in correlation. 
The statistical significance of the correlation test was set at p < 0.05.
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